These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

206 related items for PubMed ID: 29413687

  • 1. Olaratumab in soft tissue sarcoma - Current status and future perspectives.
    Antoniou G, Lee ATJ, Huang PH, Jones RL.
    Eur J Cancer; 2018 Mar; 92():33-39. PubMed ID: 29413687
    [Abstract] [Full Text] [Related]

  • 2. Assessment of the platelet-derived growth factor receptor alpha antibody olaratumab in a panel of patient-derived soft tissue sarcoma xenografts.
    Cornillie J, Wozniak A, Van Renterghem B, Van Winkel N, Wellens J, Gebreyohannes YK, Debiec-Rychter M, Sciot R, Hompes D, Schöffski P.
    BMC Cancer; 2019 Jul 22; 19(1):724. PubMed ID: 31331295
    [Abstract] [Full Text] [Related]

  • 3. Olaratumab Exerts Antitumor Activity in Preclinical Models of Pediatric Bone and Soft Tissue Tumors through Inhibition of Platelet-Derived Growth Factor Receptor α.
    Lowery CD, Blosser W, Dowless M, Knoche S, Stephens J, Li H, Surguladze D, Loizos N, Luffer-Atlas D, Oakley GJ, Guo Q, Iyer S, Rubin BP, Stancato L.
    Clin Cancer Res; 2018 Feb 15; 24(4):847-857. PubMed ID: 29191969
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Olaratumab: PDGFR-α inhibition as a novel tool in the treatment of advanced soft tissue sarcomas.
    Vincenzi B, Badalamenti G, Napolitano A, Spalato Ceruso M, Pantano F, Grignani G, Russo A, Santini D, Aglietta M, Tonini G.
    Crit Rev Oncol Hematol; 2017 Oct 15; 118():1-6. PubMed ID: 28917265
    [Abstract] [Full Text] [Related]

  • 8. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial.
    Tap WD, Jones RL, Van Tine BA, Chmielowski B, Elias AD, Adkins D, Agulnik M, Cooney MM, Livingston MB, Pennock G, Hameed MR, Shah GD, Qin A, Shahir A, Cronier DM, Ilaria R, Conti I, Cosaert J, Schwartz GK.
    Lancet; 2016 Jul 30; 388(10043):488-97. PubMed ID: 27291997
    [Abstract] [Full Text] [Related]

  • 9. Olaratumab for the treatment of advanced soft tissue sarcoma.
    Okuno SH, Maran A, Robinson SI.
    Expert Rev Anticancer Ther; 2017 Oct 30; 17(10):883-887. PubMed ID: 28862476
    [Abstract] [Full Text] [Related]

  • 10. Olaratumab: First Global Approval.
    Shirley M.
    Drugs; 2017 Jan 30; 77(1):107-112. PubMed ID: 27995580
    [Abstract] [Full Text] [Related]

  • 11. Circulating Tumor Cells and Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin: Phase Ib Study in Patients with Soft-Tissue Sarcoma.
    Martín-Broto J, Pousa AL, Brohl AS, Van Tine BA, Powers B, Stacchiotti S, Blay JY, Hu JS, Oakley GJ, Wang H, Szpurka AM, Levy DE, Mo G, Ceccarelli M, Jones RL.
    Mol Cancer Ther; 2021 Jan 30; 20(1):132-141. PubMed ID: 33177152
    [Abstract] [Full Text] [Related]

  • 12. Olaratumab for the treatment of soft tissue sarcoma.
    Deshpande HA, Cecchini M, Ni Choileain S, Jones R.
    Drugs Today (Barc); 2017 Apr 30; 53(4):247-255. PubMed ID: 28492292
    [Abstract] [Full Text] [Related]

  • 13. Olaratumab for the treatment of soft-tissue sarcoma.
    Pender A, Jones RL.
    Future Oncol; 2017 Oct 30; 13(24):2151-2157. PubMed ID: 28745071
    [Abstract] [Full Text] [Related]

  • 14. Olaratumab (Lartruvo) for soft-tissue sarcoma.
    Med Lett Drugs Ther; 2017 Aug 14; 59(1527):e138-e139. PubMed ID: 28787747
    [No Abstract] [Full Text] [Related]

  • 15. Investigating a chimeric anti-mouse PDGFRα antibody as a radiosensitizer in primary mouse sarcomas.
    Song EJ, Ashcraft KA, Lowery CD, Mowery YM, Luo L, Ma Y, Campos LDS, Cardona DM, Stancato L, Kirsch DG.
    EBioMedicine; 2019 Feb 14; 40():224-230. PubMed ID: 30711517
    [Abstract] [Full Text] [Related]

  • 16. Olaratumab for soft tissue sarcoma.
    Teyssonneau D, Italiano A.
    Expert Opin Biol Ther; 2017 Aug 14; 17(8):1019-1025. PubMed ID: 28691538
    [Abstract] [Full Text] [Related]

  • 17. The past, present, and future of cytotoxic chemotherapy and pathway-directed targeted agents for soft tissue sarcoma.
    Ryan CW, Desai J.
    Am Soc Clin Oncol Educ Book; 2013 Aug 14. PubMed ID: 23714556
    [Abstract] [Full Text] [Related]

  • 18. Combination therapy with Olaratumab/doxorubicin in advanced or metastatic soft tissue sarcoma -a single-Centre experience.
    Striefler JK, Brandes F, Baur A, Pfitzner BM, Kaul D, Rau D, Dörr A, Schmiester M, Koulaxouzidis G, Bullinger L, Märdian S, Flörcken A.
    BMC Cancer; 2020 Jan 29; 20(1):68. PubMed ID: 31996176
    [Abstract] [Full Text] [Related]

  • 19. Population Pharmacokinetic Modeling of Olaratumab, an Anti-PDGFRα Human Monoclonal Antibody, in Patients with Advanced and/or Metastatic Cancer.
    Mo G, Baldwin JR, Luffer-Atlas D, Ilaria RL, Conti I, Heathman M, Cronier DM.
    Clin Pharmacokinet; 2018 Mar 29; 57(3):355-365. PubMed ID: 28620891
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.